Hall Addresses Selection for Chemoimmunotherapy in NSCLC
Published: Monday, Sep 10, 2018
Richard D. Hall, MD
Immunotherapy has continued to expand its role in the non–small cell lung cancer (NSCLC) treatment landscape over the last few years. Now, recent data with combinations and a growing understanding of molecular abnormalities have raised questions over who is best eligible for immunotherapy and where it will optimally work, said Richard D. Hall, MD.
... to read the full story